Suppression of murine experimental autoimmune hepatitis by T‐cell vaccination or immunosuppression
Patients with autoimmune hepatitis (AIH) usually require immunosuppressive therapy for many years, if not for a lifetime. Experimental immunotherapy such as T‐cell vaccination aims at manipulating the immune system in such a way that autoimmunity is specifically regulated to enable long‐lasting corr...
Gespeichert in:
| Veröffentlicht in: | Hepatology (Baltimore, Md.) Md.), 1998-06, Vol.27 (6), p.1536-1543 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1543 |
|---|---|
| container_issue | 6 |
| container_start_page | 1536 |
| container_title | Hepatology (Baltimore, Md.) |
| container_volume | 27 |
| creator | Lohse, Ansgar W. Dienes, Hans‐Peter zum Büschenfelde, Karl‐Hermann Meyer |
| description | Patients with autoimmune hepatitis (AIH) usually require immunosuppressive therapy for many years, if not for a lifetime. Experimental immunotherapy such as T‐cell vaccination aims at manipulating the immune system in such a way that autoimmunity is specifically regulated to enable long‐lasting correction of the disease process. We aimed to test the feasibility of T‐cell vaccination as well as conventional immunosuppression in the murine model of experimental autoimmune hepatitis (EAH). EAH was induced in 5‐ to 7‐week‐old BALB/c mice by immunization with syngeneic liver homogenate in complete Freund's adjuvant. For T‐cell vaccination, splenocytes were removed from animals 14 days after induction of EAH and from control animals, and activated in vitro by mitogen stimulation with Concanavalin A (Con A). Activated T cells were irradiated and injected at 5 × 107 cells per animal as T‐cell vaccine. Immunosuppression in control animals was performed with prednisolone with or without azathioprine. T‐cell vaccination with T cells from EAH animals, but not with irrelevant T cells, was able to protect animals from EAH, reducing the average disease severity from 2.2 (±0.3) to 0.5 (±0.3) (P |
| doi_str_mv | 10.1002/hep.510270611 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79919025</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79919025</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4041-fe5172c7d46f697775922570ebfa4721c852271e8890e85990436133885e4f983</originalsourceid><addsrcrecordid>eNp9kM1KAzEUhYMotVaXLoUsxN3U_Ewmk6WUaoWCgnU9pOkdjMyfyYzanY_gM_okZmxpd64u3PNx7j0HoXNKxpQQdv0CzVhQwiRJKD1AQyqYjDgX5BAN-22kKFfH6MT7V0KIilk6QAOVMMJZPESrp65pHHhv6wrXOS47ZyvA8NmAsyVUrS6w7tralmUX9uGYbm1rPV6u8eLn69tAUeB3bYytgtB7OPzH1n5vfIqOcl14ONvOEXq-nS4ms2j-cHc_uZlHJiYxjXIQVDIjV3GSJ0pKKRRjQhJY5jqWjJpUMCYppKkikAqlSMwTynmaCohzlfIRutr4Nq5-68C3WWl9_6GuoO58JpWiijARwGgDGld77yDPmpBWu3VGSda3moWg2a7VwF9sjbtlCasdva0x6JdbXXuji9zpyli_w0IKKmWPyQ32YQtY_38zm00f9w_8AgsTkQc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79919025</pqid></control><display><type>article</type><title>Suppression of murine experimental autoimmune hepatitis by T‐cell vaccination or immunosuppression</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Lohse, Ansgar W. ; Dienes, Hans‐Peter ; zum Büschenfelde, Karl‐Hermann Meyer</creator><creatorcontrib>Lohse, Ansgar W. ; Dienes, Hans‐Peter ; zum Büschenfelde, Karl‐Hermann Meyer</creatorcontrib><description>Patients with autoimmune hepatitis (AIH) usually require immunosuppressive therapy for many years, if not for a lifetime. Experimental immunotherapy such as T‐cell vaccination aims at manipulating the immune system in such a way that autoimmunity is specifically regulated to enable long‐lasting correction of the disease process. We aimed to test the feasibility of T‐cell vaccination as well as conventional immunosuppression in the murine model of experimental autoimmune hepatitis (EAH). EAH was induced in 5‐ to 7‐week‐old BALB/c mice by immunization with syngeneic liver homogenate in complete Freund's adjuvant. For T‐cell vaccination, splenocytes were removed from animals 14 days after induction of EAH and from control animals, and activated in vitro by mitogen stimulation with Concanavalin A (Con A). Activated T cells were irradiated and injected at 5 × 107 cells per animal as T‐cell vaccine. Immunosuppression in control animals was performed with prednisolone with or without azathioprine. T‐cell vaccination with T cells from EAH animals, but not with irrelevant T cells, was able to protect animals from EAH, reducing the average disease severity from 2.2 (±0.3) to 0.5 (±0.3) (P < .01). T‐cell vaccination was also able to treat EAH, because application of the vaccine 2 weeks after induction of the disease significantly reduced disease activity at week 4 from 2.4 (±0.4) to 1.1 (±0.2) (P < .05). Both passive transfer of disease and the capacity to protect by T‐cell vaccination was mediated by CD4 T cells. Specific cellular recognition of activated disease‐inducing T cells could be detected in vaccinated animals. Immunosuppressive drugs could also suppress EAH. Thus, T‐cell vaccination in EAH is feasible and effective. Stimulation of a regulatory T‐cell network is the likely mechanism of action by which T‐cell vaccination can suppress EAH.</description><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.510270611</identifier><identifier>PMID: 9620324</identifier><identifier>CODEN: HPTLD9</identifier><language>eng</language><publisher>Philadelphia, PA: W.B. Saunders</publisher><subject>Animals ; Biological and medical sciences ; Female ; Hepatitis, Autoimmune - drug therapy ; Hepatitis, Autoimmune - immunology ; Human viral diseases ; Immunosuppression ; Immunotherapy ; Infectious diseases ; Male ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Receptors, Antigen, T-Cell - immunology ; T-Lymphocytes - immunology ; Vaccination ; Viral diseases ; Viral hepatitis</subject><ispartof>Hepatology (Baltimore, Md.), 1998-06, Vol.27 (6), p.1536-1543</ispartof><rights>Copyright © 1998 American Association for the Study of Liver Diseases</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4041-fe5172c7d46f697775922570ebfa4721c852271e8890e85990436133885e4f983</citedby><cites>FETCH-LOGICAL-c4041-fe5172c7d46f697775922570ebfa4721c852271e8890e85990436133885e4f983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.510270611$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.510270611$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2251774$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9620324$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lohse, Ansgar W.</creatorcontrib><creatorcontrib>Dienes, Hans‐Peter</creatorcontrib><creatorcontrib>zum Büschenfelde, Karl‐Hermann Meyer</creatorcontrib><title>Suppression of murine experimental autoimmune hepatitis by T‐cell vaccination or immunosuppression</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>Patients with autoimmune hepatitis (AIH) usually require immunosuppressive therapy for many years, if not for a lifetime. Experimental immunotherapy such as T‐cell vaccination aims at manipulating the immune system in such a way that autoimmunity is specifically regulated to enable long‐lasting correction of the disease process. We aimed to test the feasibility of T‐cell vaccination as well as conventional immunosuppression in the murine model of experimental autoimmune hepatitis (EAH). EAH was induced in 5‐ to 7‐week‐old BALB/c mice by immunization with syngeneic liver homogenate in complete Freund's adjuvant. For T‐cell vaccination, splenocytes were removed from animals 14 days after induction of EAH and from control animals, and activated in vitro by mitogen stimulation with Concanavalin A (Con A). Activated T cells were irradiated and injected at 5 × 107 cells per animal as T‐cell vaccine. Immunosuppression in control animals was performed with prednisolone with or without azathioprine. T‐cell vaccination with T cells from EAH animals, but not with irrelevant T cells, was able to protect animals from EAH, reducing the average disease severity from 2.2 (±0.3) to 0.5 (±0.3) (P < .01). T‐cell vaccination was also able to treat EAH, because application of the vaccine 2 weeks after induction of the disease significantly reduced disease activity at week 4 from 2.4 (±0.4) to 1.1 (±0.2) (P < .05). Both passive transfer of disease and the capacity to protect by T‐cell vaccination was mediated by CD4 T cells. Specific cellular recognition of activated disease‐inducing T cells could be detected in vaccinated animals. Immunosuppressive drugs could also suppress EAH. Thus, T‐cell vaccination in EAH is feasible and effective. Stimulation of a regulatory T‐cell network is the likely mechanism of action by which T‐cell vaccination can suppress EAH.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Hepatitis, Autoimmune - drug therapy</subject><subject>Hepatitis, Autoimmune - immunology</subject><subject>Human viral diseases</subject><subject>Immunosuppression</subject><subject>Immunotherapy</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Inbred C57BL</subject><subject>Receptors, Antigen, T-Cell - immunology</subject><subject>T-Lymphocytes - immunology</subject><subject>Vaccination</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1KAzEUhYMotVaXLoUsxN3U_Ewmk6WUaoWCgnU9pOkdjMyfyYzanY_gM_okZmxpd64u3PNx7j0HoXNKxpQQdv0CzVhQwiRJKD1AQyqYjDgX5BAN-22kKFfH6MT7V0KIilk6QAOVMMJZPESrp65pHHhv6wrXOS47ZyvA8NmAsyVUrS6w7tralmUX9uGYbm1rPV6u8eLn69tAUeB3bYytgtB7OPzH1n5vfIqOcl14ONvOEXq-nS4ms2j-cHc_uZlHJiYxjXIQVDIjV3GSJ0pKKRRjQhJY5jqWjJpUMCYppKkikAqlSMwTynmaCohzlfIRutr4Nq5-68C3WWl9_6GuoO58JpWiijARwGgDGld77yDPmpBWu3VGSda3moWg2a7VwF9sjbtlCasdva0x6JdbXXuji9zpyli_w0IKKmWPyQ32YQtY_38zm00f9w_8AgsTkQc</recordid><startdate>199806</startdate><enddate>199806</enddate><creator>Lohse, Ansgar W.</creator><creator>Dienes, Hans‐Peter</creator><creator>zum Büschenfelde, Karl‐Hermann Meyer</creator><general>W.B. Saunders</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199806</creationdate><title>Suppression of murine experimental autoimmune hepatitis by T‐cell vaccination or immunosuppression</title><author>Lohse, Ansgar W. ; Dienes, Hans‐Peter ; zum Büschenfelde, Karl‐Hermann Meyer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4041-fe5172c7d46f697775922570ebfa4721c852271e8890e85990436133885e4f983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Hepatitis, Autoimmune - drug therapy</topic><topic>Hepatitis, Autoimmune - immunology</topic><topic>Human viral diseases</topic><topic>Immunosuppression</topic><topic>Immunotherapy</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Inbred C57BL</topic><topic>Receptors, Antigen, T-Cell - immunology</topic><topic>T-Lymphocytes - immunology</topic><topic>Vaccination</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lohse, Ansgar W.</creatorcontrib><creatorcontrib>Dienes, Hans‐Peter</creatorcontrib><creatorcontrib>zum Büschenfelde, Karl‐Hermann Meyer</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lohse, Ansgar W.</au><au>Dienes, Hans‐Peter</au><au>zum Büschenfelde, Karl‐Hermann Meyer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Suppression of murine experimental autoimmune hepatitis by T‐cell vaccination or immunosuppression</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>1998-06</date><risdate>1998</risdate><volume>27</volume><issue>6</issue><spage>1536</spage><epage>1543</epage><pages>1536-1543</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><coden>HPTLD9</coden><abstract>Patients with autoimmune hepatitis (AIH) usually require immunosuppressive therapy for many years, if not for a lifetime. Experimental immunotherapy such as T‐cell vaccination aims at manipulating the immune system in such a way that autoimmunity is specifically regulated to enable long‐lasting correction of the disease process. We aimed to test the feasibility of T‐cell vaccination as well as conventional immunosuppression in the murine model of experimental autoimmune hepatitis (EAH). EAH was induced in 5‐ to 7‐week‐old BALB/c mice by immunization with syngeneic liver homogenate in complete Freund's adjuvant. For T‐cell vaccination, splenocytes were removed from animals 14 days after induction of EAH and from control animals, and activated in vitro by mitogen stimulation with Concanavalin A (Con A). Activated T cells were irradiated and injected at 5 × 107 cells per animal as T‐cell vaccine. Immunosuppression in control animals was performed with prednisolone with or without azathioprine. T‐cell vaccination with T cells from EAH animals, but not with irrelevant T cells, was able to protect animals from EAH, reducing the average disease severity from 2.2 (±0.3) to 0.5 (±0.3) (P < .01). T‐cell vaccination was also able to treat EAH, because application of the vaccine 2 weeks after induction of the disease significantly reduced disease activity at week 4 from 2.4 (±0.4) to 1.1 (±0.2) (P < .05). Both passive transfer of disease and the capacity to protect by T‐cell vaccination was mediated by CD4 T cells. Specific cellular recognition of activated disease‐inducing T cells could be detected in vaccinated animals. Immunosuppressive drugs could also suppress EAH. Thus, T‐cell vaccination in EAH is feasible and effective. Stimulation of a regulatory T‐cell network is the likely mechanism of action by which T‐cell vaccination can suppress EAH.</abstract><cop>Philadelphia, PA</cop><pub>W.B. Saunders</pub><pmid>9620324</pmid><doi>10.1002/hep.510270611</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-9139 |
| ispartof | Hepatology (Baltimore, Md.), 1998-06, Vol.27 (6), p.1536-1543 |
| issn | 0270-9139 1527-3350 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79919025 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Animals Biological and medical sciences Female Hepatitis, Autoimmune - drug therapy Hepatitis, Autoimmune - immunology Human viral diseases Immunosuppression Immunotherapy Infectious diseases Male Medical sciences Mice Mice, Inbred BALB C Mice, Inbred C57BL Receptors, Antigen, T-Cell - immunology T-Lymphocytes - immunology Vaccination Viral diseases Viral hepatitis |
| title | Suppression of murine experimental autoimmune hepatitis by T‐cell vaccination or immunosuppression |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T08%3A41%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Suppression%20of%20murine%20experimental%20autoimmune%20hepatitis%20by%20T%E2%80%90cell%20vaccination%20or%20immunosuppression&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Lohse,%20Ansgar%20W.&rft.date=1998-06&rft.volume=27&rft.issue=6&rft.spage=1536&rft.epage=1543&rft.pages=1536-1543&rft.issn=0270-9139&rft.eissn=1527-3350&rft.coden=HPTLD9&rft_id=info:doi/10.1002/hep.510270611&rft_dat=%3Cproquest_cross%3E79919025%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79919025&rft_id=info:pmid/9620324&rfr_iscdi=true |